Kura Oversubscribed $150 Million Private Placement

  Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital –

– Pro forma cash, cash equivalents and investments expected to provide runway into 2027 –

– Management to host virtual investor event at 8:00 a.m. ET on January 30 to highlight preliminary combination data for ziftomenib –

Kura will host a virtual investor event featuring company management and investigators from the KOMET-007 trial of ziftomenib in combination with standards of care at 8:00 a.m. ET on Tuesday, January 30, 2024. The event will be webcast live and can be accessed on the Investors section of Kura’s website at www.kuraoncology.com. An archived replay will be available shortly after the conclusion of the live event.

https://www.globenewswire.com/news-release/2024/01/24/2815114/35186/en/Kura-Oncology-Announces-Oversubscribed-150-Million-Private-Placement.html